“Tumor-targeted costimulatory trimerbodies for cancer immunotherapy.”- A brief discussion with Juan Perez Villar, CEO, LeadArtis.
Doctor in Immunology from the Autonomous University of Madrid (Spain), extensive international career in the biopharmaceutical industry at Astellas Inc. and Bristol-Myers Squibb Co. (USA). Experienced R&D leader in immune-oncology (IO). Previously, participated in preclinical development of CD28 biologic modulators for inflammatory conditions, small molecule tyrosine kinase inhibitors and fully human antibodies for advanced solid […]